Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds

The top 20 global biopharmaceutical companies experienced mixed performances in their individual market capitalisations in the third quarter (Q3) of 2025, amid headwinds from US President Donald Trump’s tariffs and drug pricing pressures, with companies that demonstrated robust pipeline development reaping success. As a result, their combined market capitalisation rose 4% from $3.7 trillion (trn) on 30 June 2025 to $3.8trn on 30 September 2025, according to GlobalData, a leading data analytics and research ...